Arca
Skip to content
Tools
Tools

PARP 1, 2 and 3

Family in Homo sapiens that 4 drugs act on.

  • Drugs that act on it: 4
  • Approved: 2
  • In phases 1 to 3: 2
  • Sponsors: 4
  • Genes: 3

Who is on it, and how far along

Every drug ChEMBL records acting on PARP1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 4

Approved2

  • Olaparib
  • Rucaparib

Phase 31

  • Veliparib

Phase 21

  • E-7016

Phase 10

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    The landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: PARP 1, 2 and 3 inhibitor.
    OlaparibApprovedAstraZeneca PharmaceuticalsSmall moleculeInhibitor229
    RucaparibApprovedBristol-Myers SquibbSmall moleculeInhibitor12
    VeliparibPhase 3AbbVieSmall moleculeInhibitor13
    E-7016Phase 2EisaiSmall moleculeInhibitor0

    Open trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 24 in all, from ClinicalTrials.gov.
    PARP Inhibition for Biliary Tract Cancer With Mutations in Core and Non-Core Homologous Recombination Deficiency GenesOlaparibPhase 2Not yet recruitingInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestNov 16, 2026
    Phase Ib/II Clinical Study of QLS5133 Combination Therapy in Advanced Solid TumorsOlaparibPhase 1 / Phase 2Not yet recruitingQilu Pharmaceutical Co., Ltd.Nov 12, 2026
    Phase 1/2 Study Of PARP Inhibition With Olaparib To Enhance The Efficacy Of High-Dose Chemotherapy In Refractory And Relapsed Germ Cell TumorsOlaparibPhase 1 / Phase 2Not yet recruitingM.D. Anderson Cancer CenterOct 1, 2026
    Molecularly Tailored Therapy in Advanced Pancreatic CancerOlaparibPhase 2Not yet recruitingHerlev HospitalSep 3, 2026
    Olaparib+Trastuzumab+Pertuzumab Neoadjuvant for Elderly HER2+ Breast CancerOlaparibPhase 4RecruitingWen-Ming CaoJul 10, 2026
    PROLONG (PRostateOLaparibONcombinationGcc) StudyOlaparib—Not yet recruitingAstraZenecaJun 29, 2026
    Rucaparib Monoclonal Antibody for Lorlatinib-Induced Hypercholesterolemia / MixedRucaparibPhase 4Not yet recruitingHunan Cancer HospitalJun 29, 2026
    An Exploratory Study on the Use of Ipalotinib (Tislelizumab) Combined With Sunitinib and Olaparib for Neoadjuvant Therapy in HRD-positive Advanced Ovarian CancerOlaparibPhase 2RecruitingBai-Rong XiaJun 25, 2026
    Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast CancerOlaparibPhase 1RecruitingImmunomic Therapeutics, Inc.Jun 17, 2026
    Telmisartan in Prostate CancerRucaparibPhase 1RecruitingTyler J CurielDec 13, 2023
    Microdevice In Ovarian, Fallopian Tube, And Peritoneal CancerRucaparibPhase 1RecruitingBrigham and Women's HospitalJan 8, 2021
    A Study of Rucaparib and Nivolumab in People With LeiomyosarcomaRucaparibPhase 2Active, not recruitingMemorial Sloan Kettering Cancer CenterNov 10, 2020
    A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation TherapyRucaparibPhase 3Active, not recruitingAlliance for Clinical Trials in OncologyJul 2, 2020
    A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate CancerRucaparibPhase 1 / Phase 2Active, not recruitingBrown UniversityFeb 5, 2020
    Pan Tumor Rollover StudyRucaparibPhase 2RecruitingBristol-Myers SquibbApr 2, 2019
    A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab StudyRucaparibPhase 3Active, not recruitingHoffmann-La RocheDec 7, 2018
    Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 MutationsVeliparibPhase 2Active, not recruitingChildren's Oncology GroupJul 10, 2018
    Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic LeukemiaVeliparibPhase 2Active, not recruitingNational Cancer Institute (NCI)Sep 21, 2017
    Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma MultiformeVeliparibPhase 2 / Phase 3Active, not recruitingNational Cancer Institute (NCI)Jun 2, 2014
    Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung CancerVeliparibPhase 2Active, not recruitingNational Cancer Institute (NCI)Jul 11, 2012
    Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic CancerVeliparibPhase 2Active, not recruitingNational Cancer Institute (NCI)Apr 26, 2012
    Veliparib and Dinaciclib in Treating Patients With Advanced Solid TumorsVeliparibPhase 1Active, not recruitingNational Cancer Institute (NCI)Sep 14, 2011
    Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by SurgeryVeliparibPhase 1 / Phase 2Active, not recruitingNational Cancer Institute (NCI)Jul 1, 2011
    Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney DysfunctionVeliparibPhase 1Active, not recruitingNational Cancer Institute (NCI)Jun 3, 2011

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3390820, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

    Esc

    Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

    Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.